Concepedia

Fredrik Erlandsson

FE

25

Publications

1.8K

Citations

20

H-Index

2000

Active since

Affiliations

Karolinska Institutet(Current)

AstraZeneca (Sweden)

Karolinska University Hospital

Uppsala University

Inserm

Fredrik Erlandsson is an author at Karolinska Institutet specializing in medicine, cancer therapeutics, and oncology.

ORCID

Top concepts

Publications per year

2000–2020

25

Publications

25

A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma

Jonathan E. Rosenberg, Richard Bambury, Eliezer M. Van Allen et al. · Investigational New Drugs · 2013 · 399 citations · Full text

, , +5

Combining intensity, edge and shape information for 2D and 3D segmentation of cell nuclei in tissue sections

Carolina Wählby, Ida‐Maria Sintorn, Fredrik Erlandsson et al. · Journal of Microscopy · 2004 · 354 citations

, , +28

Tralokinumab for moderate-to-severe UC: a randomised, double-blind, placebo-controlled, phase IIa study

Silvio Danese, J Rudziński, Wolfgang Brandt et al. · Gut · 2014 · 151 citations

A Phase 1 Study of AS1409, a Novel Antibody-Cytokine Fusion Protein, in Patients with Malignant Melanoma or Renal Cell Carcinoma

Sarah Maria Rudman, Michael B. Jameson, Mark J. McKeage et al. · Clinical Cancer Research · 2011 · 107 citations · Full text

Sequential immunofluorescence staining and image analysis for detection of large numbers of antigens in individual cell nuclei

Carolina Wählby, Fredrik Erlandsson, Ewert Bengtsson et al. · Cytometry · 2001 · 88 citations

Rows per page

1–5 of 25